OBJECTIVE: This open-label clinical trial primarily examined the safety and tolerability of ketamine treatment in patients with mild cognitive impairment and Major Depressive Disorder (MCI-D). Preliminary efficacy was also explored. METHODS: The trial was conducted between November 2023 and March 2025. Patients with MCI-D and moderate to severe symptom levels of depression received a single...
Objective: While inflammatory dysregulation is well-documented in major depressive disorder (MDD), its response to esketamine treatment in adolescents remains poorly understood. We aimed to examine the effects of esketamine on the inflammatory cytokines in adolescent MDD. Methods: This randomized, double-blind trial assigned 49 adolescents with MDD to receive three infusions of esketamine or...
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant effects and safety of repeated low doses of psilocybin in participants diagnosed with MDD. DESIGN This was a Phase II, randomized, double-blind, placebo-controlled clinical trial. SETTING The trial was conducted from July 2022 to December 2024 at two...
Abstract Background Migrant children often experience greater anxiety and depression than their local peers due to challenges in adapting to urban life. Emotional resilience and mindfulness may serve as protective factors for mental health, but their influence on migrant children’s emotional well-being is not well understood. This study explored differences in anxiety, depression, mindfulness,...
Background/Objectives: Intranasal esketamine has emerged as an effective treatment for patients with treatment-resistant depression (TRD), providing rapid symptom relief when conventional antidepressant strategies fail. While its pharmacological efficacy has been demonstrated in randomized controlled trials, less attention has been paid to the organizational, relational, and multidisciplinary...
1. Esketamine as monotherapy or adjunct to conventional antidepressants is proven efficacious in clinical trials in adults with treatment-resistant depression (TRD) and depression with high risk of...
Ketamine, esketamine, rTMS and ECT are associated with reductions in SI in persons with MDD, with the strongest evidence from randomized controlled trials supporting rapid, short-term effects, particularly for ketamine and esketamine. Further characterization and differentiation of the durability of antisuicidal effects of the aforementioned interventions requires investigation in large-scale,...
Internet gaming disorder (IGD) has been recognized as a serious mental illness and is often accompanied by depression (IGD-D). An ideal treatment strategy should have effects on both the conditions. Mindfulness meditation (MM) has attracted substantial attention for the treatment of psychiatric diseases; however, its effects on IGD-D and the underlying mechanisms remain unknown. A total of 70...
Medical Science MonitorFebruary 18, 2026Łukasz Grabarczyk, Sophia Rebekka Wolfermann, Hubert Oniszczuk et al.
Conventional antidepressant drugs are effective in only approximately 50% of patients with treatment-resistant depression (TRD). Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, offers a promising alternative with an exceptionally rapid antidepressant effect. Although its efficacy in the general TRD population is well established, its use in specific patient subpopulations...